RE:Ad on www.wallstreet-online.de This is of high relevance right now.
"Dr. Deliencourt-Godefroy: We are not targeting the same biological pathway as Merck & Co. and Pfizer, because we are not focusing on the virus, but on the host cell. This seems strange, but it is the only way to avoid resistance to viral mutations. In addition, by targeting the host cell, we have the opportunity to develop a broad-spectrum antiviral. In this field, there is a need to use multiple approaches to obtain a highly efficient treatment."